Evidence map›Paper›PMID 26753011›Full record

ArticleClinical epigenetics2016

"Monoallelic germline methylation and sequence variant in the promoter of the RB1 gene: a possible constitutive epimutation in hereditary retinoblastoma".

Guadalupe Quiñonez-Silva, Mercedes Dávalos-Salas, Félix Recillas-Targa, Patricia Ostrosky-Wegman, Diego Arenas Aranda, Luis Benítez-Bribiesca

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Clinical epigenetics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
10.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 148 citations in OpenAlex.

  1. Article
  2. Review
  3. Impact of anthracycline-based chemotherapy on RB1 gene methylation in peripheral blood leukocytes and biomarkers of oxidative stress and inflammation in sarcoma patients.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024
    Article
  4. Review
  5. Article
  6. Decrease ofFrontiers in medicine · 2022
    Article
  7. Article
  8. Review
  9. Observational
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Guadalupe Quiñonez-SilvaHospital de Pediatría, Centro Médico Nacional Siglo XXI, IMSS, Unidad de Investigación Médica en Genética Humana, México, D.F. Mexico.
Mercedes Dávalos-SalasDepartamento de Genética Molecular, Instituto de Fisiología Celular, Universidad Nacional Autónoma de México (UNAM), México, D.F. Mexico.
Félix Recillas-TargaDepartamento de Genética Molecular, Instituto de Fisiología Celular, Universidad Nacional Autónoma de México (UNAM), México, D.F. Mexico.
Patricia Ostrosky-WegmanLaboratorio de Genómica, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México (UNAM), México, D.F. Mexico.
Diego Arenas ArandaHospital de Pediatría, Centro Médico Nacional Siglo XXI, IMSS, Unidad de Investigación Médica en Genética Humana, México, D.F. Mexico.
Luis Benítez-BribiescaHospital de Oncología, CMNS-XXI, IMSS, Unidad de Investigación Médica en Enfermedades Oncológicas, Av. Cuauhtémoc 330, 06725 México, D.F. Mexico.
Universidad Nacional Autónoma de México · MXCentro Medico Nacional Siglo XXI · MXMexican Social Security Institute · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRetinoblastoma is a malignant tumor of the retina in children <5 years of age and occurs after two mutations in the RB1 gene. The first mutation (M1) is germinal and confers predisposition to the hereditary type, which is transmitted as an autosomal dominant highly penetrant trait, so 90 % of carriers develop retinoblastoma; however, 10 % of carriers either do not develop the tumor or develop it unilaterally. Most mutations are point mutations. Inactivation of the RB1 gene is usually caused by mutations affecting the coding region. Silencing by methylation of the RB1 promoter has been observed in retinoblastoma tumors as a second mutation (M2) and is classified as somatic epimutation. Germline methylation of the RB1 gene promoter was studied in a particular pedigree of six generations from the paternal side, with incomplete penetrance and bias towards healthy male carriers and those affected with unilateral retinoblastoma.

resultsThe methylation status of the 27 CpGs dinucleotides that constitute the core of the RB1 gene promoter, analyzed by cloning and genomic sequencing after DNA sodium bisulfite conversion, demonstrated a monoallelic methylation pattern which coincides with a c. [-187T > G; -188T > G] sequence variant that is found in peripheral blood lymphocytes and tumor DNA. Unexpectedly, it was the mother who transmitted this variant to two more generations. Microsatellite markers of D chromosome showed a biparental contribution of both D13 chromosomes to the retinoblastoma phenotype, conferring double heterozygosity in the affected cases.

conclusionsThe monoallelic genetic-epigenetic finding, the sequence variant, and methylation suggest a constitutive epimutation and probably a genetic-epigenetic hereditary predisposition for retinoblastoma in this family.

Indexed as

AllelesChild, PreschoolDNA MethylationEpigenesis, GeneticFemaleGenetic Predisposition to DiseaseGerm CellsHeterozygoteHumansInfantMaleMicrosatellite RepeatsPedigreePoint MutationPromoter Regions, GeneticRetinal NeoplasmsRetinoblastoma ProteinConstitutive epimutationGenetic-epigenetic predispositionMethylationRB1-promoterSequence variant

Identifiers

PMID26753011
PMCPMC4706693
OpenAlexW2232156689

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.